These immunosuppressive TME and aggressive tumor phenotype are blocked by CHI3L1 nAbs through shifting M2 to anti-tumor M1, decreasing Tregs/CD8+ T ratio and attenuating oncogenic cancer signaling to reduce tumor growth and metastases. This evidence concerns the gene CD8A and cancer.